This educational program is intended for medical oncologists and other healthcare professionals who treat patients with cancer.
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to apply practice-changing clinical data and expert recommendations to optimally integrate histology-agnostic therapies into treatment of eligible patients with cancer.
Appraise emerging clinical efficacy and safety data supporting the use of histology-agnostic therapies in solid tumors
Formulate strategies for integrating histology-agnostic agents into the management of eligible patients with cancer based on biomarker assessment, current evidence as well as expert and guideline recommendations
Order appropriate assays or molecular tests to detect oncogenic gene fusions, mutations, and other targetable genomic alterations in patients with malignant solid tumors
Identify and refer eligible patients with appropriate biomarkers for enrollment in ongoing clinical trials investigating histology-agnostic therapies
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Chul Kim, MD, MPH
Department of Medicine, Division of Hematology and Oncology
Georgetown Lombardi Comprehensive Cancer Center
Chul Kim, MD, MPH: consultant/advisor/speaker: Arcus, AstraZeneca, Daiichi Sankyo, Diffusion, Eisai, Janssen, Jazz, Mirati, Novartis, PierianDx, Regeneron, Sanofi; researcher: AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Debiopharm, Genentech, Janssen, Karyopharm, Lyell Immunopharma, Merck, Novartis, Regeneron.
Sapna P. Patel, MD
Chair, SWOG Melanoma Committee
SWOG Cancer Research Network
Associate Professor, Director of the Uveal Melanoma Program
The University of Texas MD Anderson Cancer Center
Sapna P. Patel, MD: consultant/advisor/speaker: Bristol-Myers Squibb, Cardinal Health, Castle Biosciences, Delcath, Guidepoint Global, Hexal/Sandoz, Immatics, Immunocore, Novartis, OncoSec, Pfizer, Replimune, Terranova Medica, TriSalus Life Sciences; researcher: Bristol-Myers Squibb, Foghorn Therapeutics, Ideaya, InxMed, Lyvgen, Novartis, Provectus, Seagen, Syntrix Bio, TriSalus Life Sciences
Jonathan Trent, MD, PhD
Professor of Medicine
Department of Medical Oncology
Miller School of Medicine
Sylvester Comprehensive Cancer Center
Jonathan Trent, MD, PhD: consultant/advisor/speaker: Aadi, Adcendo, Bayer, Blueprint, Boehringer Ingelheim, Cogent, Deciphera, Foghorn.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 06, 2023, through June 05, 2024:
You must respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.